Merck Needs Biotech Startups More Than EverSarah Lacy
It’s day two at the JP Morgan Healthcare conference and the morning started with big pharma presentations. The most anticipated seemed to be Merck & Co. Inc., still reeling from the Vioxx recall.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.